Stages of change, smoking characteristics, and cotinine concentrations in smokers: Setting priorities for smoking cessation


Por: Fu, M, Fernandez, E, Pascual, JA, Martinez-Sanchez, JM, Agudo, A, Moncada, A, Nebot, M, Borras, JM

Publicada: 1 feb 2011
Resumen:
Objective. We assessed whether the salivary cotinine content of daily smokers varied with the readiness to quit and smoking characteristics. Methods. This cross-sectional study was conducted in Barcelona, Spain (n=1245) in 2004-2005. We administered a questionnaire to assess smoking behaviour and collected saliva to determine the cotinine content. We determined the distribution of 278 adult daily smokers across different stages of change and categorised them by individual and smoking characteristics. We used medians and interquartile ranges (IQR) to relate cotinine concentrations to different stages of change, tobacco consumption, and nicotine dependence based on the Fagerstrom Test for Nicotine Dependence (FTND). Results. Around 68%, 22%, and 11% of smokers were in precontemplation, contemplation, and preparation stages, respectively. A mean of 17.0 cigarettes was smoked daily, with no differences among stages of change. The median cotinine concentration was 151.3 ng/ml (IQR: 83.2-227.8 ng/ml), with no differences among stages of change. The cigarette consumption scores, FIND, and time to first cigarette of the day were positively associated with cotinine concentration. Conclusions. The cotinine concentration was similar among the stages of change, but varied within each stage according to the number of cigarettes smoked, time to first cigarette of the day, and nicotine dependence. (C) 2010 Elsevier Inc. All rights reserved.

Filiaciones:
Fu, M:
 Inst Invest Biomed Bellvitge IDIBELL, Canc Control & Prevent Grp, Lhospitalet De Llobregat 08908, Barcelona, Spain

 Univ Barcelona, Dept Clin Sci, Lhospitalet De Llobregat 08907, Barcelona, Spain

Fernandez, E:
 Catalan Inst Oncol, Tobacco Control Unit, Canc Control & Prevent Programme, Inst Catala Oncol, Lhospitalet De Llobregat 08908, Barcelona, Spain

 Inst Invest Biomed Bellvitge IDIBELL, Canc Control & Prevent Grp, Lhospitalet De Llobregat 08908, Barcelona, Spain

 Univ Barcelona, Dept Clin Sci, Lhospitalet De Llobregat 08907, Barcelona, Spain

Pascual, JA:
 IMIM Hosp Mar Res Inst, Bioanal Res Grp, Neuropsychopharmacol Programme, Barcelona 08003, Spain

Martinez-Sanchez, JM:
 Inst Invest Biomed Bellvitge IDIBELL, Canc Control & Prevent Grp, Lhospitalet De Llobregat 08908, Barcelona, Spain

 Univ Barcelona, Dept Clin Sci, Lhospitalet De Llobregat 08907, Barcelona, Spain

Agudo, A:
 ICO, Nutr Environm & Canc Unit, Lhospitalet De Llobregat 08908, Barcelona, Spain

 Inst Invest Biomed Bellvitge IDIBELL, Nutr Environm & Canc Grp, Lhospitalet De Llobregat 08908, Barcelona, Spain

Moncada, A:
 Ajuntament Terrassa, Terrassa 08223, Spain

Nebot, M:
 ASPB, Evaluat & Intervent Methods Unit, Barcelona 08023, Spain

 Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona 08003, Spain

 CIBERSP, Barcelona 08003, Spain

Borras, JM:
 Inst Invest Biomed Bellvitge IDIBELL, Canc Control & Prevent Grp, Lhospitalet De Llobregat 08908, Barcelona, Spain

 Univ Barcelona, Dept Clin Sci, Lhospitalet De Llobregat 08907, Barcelona, Spain

 Generalitat Catalunya, Dept Hlth, Lhospitalet De Llobregat 08908, Barcelona, Spain
ISSN: 00917435





PREVENTIVE MEDICINE
Editorial
ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 52 Número: 2
Páginas: 139-145
WOS Id: 000286961800010
ID de PubMed: 21163297

MÉTRICAS